Editas Medicine stock (US28106W1036): Recent clinical updates keep investors focused
Editas Medicine (EDIT) remains a high-risk, event-driven biotech stock, with investor interest focused on its CRISPR-focused pipeline and cash runway. The company's value is driven by data from ongoing studies and its ability to fund development, making pipeline execution and clinical readouts critical for stock movement. Investors are particularly watching for scientifically meaningful updates rather than broad market trends.
Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)
This article indicates that analyst sentiment towards Editas Medicine (NASDAQ:EDIT) has become more bearish. The content provided is incomplete, but the title suggests a negative shift in financial outlook from analysts regarding the company's future performance.
Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)
Analysts have issued a significantly more bearish forecast for Editas Medicine, Inc. (NASDAQ:EDIT), sharply reducing revenue estimates for 2026 to US$14m, a 63% reduction from the previous year. While loss per share is expected to slightly improve to US$1.01, the substantial cut in revenue, coupled with an accelerated decline rate worse than the broader industry, suggests a more cautious outlook for the company. The report also highlights concerns about dilutive stock issuance as a potential financial risk.
Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)
Analysts have revised their forecasts for Editas Medicine (NASDAQ:EDIT), adopting a more bearish stance. They have significantly cut revenue estimates for 2026 to US$14 million, a 63% reduction, while maintaining a loss per share of US$1.01. This downgrade suggests that Editas Medicine's revenue decline is expected to accelerate and perform worse than the broader industry.
Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data
Editas Medicine reported promising preclinical data for its gene-editing therapy, EDIT-401, designed to treat hyperlipidemia. The data, presented at a scientific meeting, showed significant and durable LDL cholesterol reduction in non-human primates, along with a favorable safety profile. These findings suggest EDIT-401 could be a potential best-in-class, one-time treatment, bolstering Editas's position in cardiometabolic gene therapy.
Editas Medicine presents preclinical data on EDIT-401 therapy By Investing.com
Editas Medicine presented positive preclinical data on its gene editing treatment candidate, EDIT-401, for hyperlipidemia at recent scientific conferences. The data showed that EDIT-401 significantly reduced LDL cholesterol in non-human primates and suggested potential for dose adjustments in human patients with Heterozygous Familial Hypercholesterolemia. This progress strengthens confidence in EDIT-401 as a potential one-time treatment and supports its advancement towards human clinical trials.
Editas Reports ≥90% Mean LDL-C Reduction with Single EDIT-401 Dose in NHPs; Durable ~6 Months
Editas (EDIT) reported significant results for its EDIT-401 treatment, showing a mean LDL-C reduction of 90% in non-human primates after a single dose. This reduction was sustained for approximately six months. The company also noted no adverse clinical observations at therapeutically relevant doses, with promising implications for HeFH patients based on mouse PK/PD data.
EDIT-401 preclinical data show ≥90% LDL-C drop in primates (EDIT)
Editas Medicine reported new preclinical data for its gene-editing candidate EDIT-401, showing a ≥90% reduction in LDL cholesterol in non-human primates for approximately six months after a single dose. These promising results, along with a favorable safety profile at therapeutically relevant doses and supportive mouse data, are advancing EDIT-401 towards first-in-human clinical trials for hyperlipidemia. The company highlighted the broader potential of its upregulation strategy and the use of DNA large language prediction models in gene editing.
Gene editing test from Editas cuts LDL cholesterol 90% in monkeys
Editas Medicine announced new preclinical data for its gene-editing candidate, EDIT-401, showing significant LDL cholesterol reduction in non-human primates. A single dose led to a 90% mean reduction in LDL-C for approximately six months, with a promising safety profile. This data supports the continued advancement of EDIT-401 towards human clinical trials for hyperlipidemia.
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Editas Medicine announced new preclinical data for EDIT-401, demonstrating its potential as a one-time treatment for hyperlipidemia. The data show durable LDL-C lowering of over 90% and a promising safety profile in non-human primates, with effects lasting around six months from a single dose. These findings support the continued advancement of EDIT-401 towards human clinical trials.
Editas Medicine presents new in vivo gene editing data on EDIT-401 at TIDES USA 2026 Meeting
Editas Medicine presented new in vivo gene editing data for its lead development candidate, EDIT-401, at the TIDES USA 2026 Meeting. This presentation underscores the company's dedication to advancing gene editing therapies for cardiovascular diseases. Editas has consistently shared preclinical data at major scientific events and recently provided a business update that included its first-quarter 2026 results.
Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Editas Medicine (NASDAQ:EDIT) from a "hold" to a "sell" rating, contributing to a mixed analyst sentiment that still includes multiple "buy" ratings. Despite the downgrade, Editas Medicine's stock was up 2.6% and opened at $3.11, with a market capitalization of approximately $304.5 million. The company recently exceeded EPS expectations but fell short on revenue, and analysts project a full-year loss.
Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates
Editas Medicine, Inc. (NASDAQ:EDIT) recently reported first-quarter results that showed a significant revenue miss but in-line losses. Despite the revenue decline, analysts have raised their revenue estimates for 2026 and increased the price target to US$6.38, even while forecasting higher losses per share. The company's revenues have been declining over the past five years, with analysts expecting this trend to accelerate, performing worse than the wider industry.
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT) has received a "Moderate Buy" consensus rating from seven analysts, with an average 1-year price target of $5.40. The company recently reported quarterly EPS of -$0.26, beating estimates, though revenue of $2.83 million missed the consensus and it remains unprofitable. The stock trades near $3.03, with institutional investors holding approximately 71.9% of shares.
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas Medicine (EDIT) reported a Q1 2026 loss of 26 cents per share, which was narrower than the Zacks Consensus Estimate of 30 cents, driven by lower operating expenses. Despite a 39.2% decrease in collaboration and R&D revenues, the company's shares rose 48.3% year-to-date. Editas is now focusing on its in vivo pipeline, particularly EDIT-401 for hypercholesterolemia, with preclinical results showing significant LDL-C reduction and plans to initiate a first-in-human study later this year.
Editas Medicine posts first quarter 2026 results and provides business update
Editas Medicine announced its financial results for the first quarter of 2026, alongside business updates. The company, focused on gene editing for cardiovascular disease and hyperlipidemia, also stated plans to present new preclinical data on gene editing at upcoming scientific conferences, with an emphasis on cardiovascular research. Investors are watching Editas Medicine's advancements in biotechnology and therapeutic innovations closely.
Editas targets human testing this year for a one-shot cholesterol gene edit
Editas Medicine announced its Q1 2026 results, highlighting significant progress on EDIT-401, a gene-editing therapy for hyperlipidemia, which showed over 90% LDL-C reduction in preclinical studies and is on track for human trials later in 2026. The company reported a narrowed net loss of $25.0 million and a cash runway extending into Q3 2027. Editas also plans to present new preclinical data at several upcoming scientific meetings.
Editas: Q1 Earnings Snapshot
Editas Medicine Inc. (EDIT) reported a first-quarter loss of $25 million, or 26 cents per share, which exceeded Wall Street expectations. However, the genome editing company's revenue of $2.8 million for the period fell short of analysts' forecasts. This financial snapshot highlights Editas's mixed performance in its latest earnings report.
Chardan Capital Boosts Editas Medicine (NASDAQ:EDIT) Price Target to $4.00
Chardan Capital has increased its price target for Editas Medicine (NASDAQ:EDIT) from $3.50 to $4.00, maintaining a "buy" rating and suggesting a 32.45% upside. This comes as analysts generally hold a "Moderate Buy" consensus with an average price target of $5.40. Despite beating EPS estimates, Editas Medicine missed revenue targets, but its shares rose by 0.7% to $3.02, reflecting cautious optimism for the clinical-stage biotech focused on gene-editing therapies.
Editas Medicine (NASDAQ: EDIT) cuts Q1 2026 loss as spending falls
Editas Medicine reported a significantly narrowed net loss of $25.0 million in Q1 2026, improved from $76.1 million in Q1 2025, primarily due to reduced operating costs and the absence of prior restructuring charges. The company's cash and cash equivalents totaled $123.6 million, projected to fund operations into Q3 2027 as it advances its lead gene-editing candidate, EDIT-401, towards clinical trials. Despite a decrease in collaboration revenue, the financial improvement is attributed to cost-cutting measures, including workforce reductions and the discontinuation of the reni-cel program.
Editas Medicine Releases Q1 2026 Financial Results
Editas Medicine, Inc. reported a narrower loss for the first quarter of 2026, with a loss per share of $0.26, significantly improved from $0.92 in the prior year. Despite a 39.2% decline in revenue to $2.8M, the company demonstrated progress in managing operating expenses and controlling cash burn. Wall Street analysts maintain a generally positive outlook on the stock.
Editas Medicine (Nasdaq: EDIT) trims Q1 2026 net loss to $25M
Editas Medicine announced a significant reduction in its net loss for Q1 2026, narrowing it to $25.0 million from $76.1 million in the prior year, primarily due to lower R&D and G&A expenses and the absence of restructuring charges. The company is advancing its lead in vivo gene-editing program, EDIT-401, for hyperlipidemia and HeFH, with preclinical data showing over 90% mean LDL-C reduction and plans for a first-in-human trial in 2026. Editas expects its current cash and cash equivalents of $123.6 million to fund operations into Q3 2027.
Editas: Q1 Earnings Snapshot
Editas Medicine Inc. (EDIT) reported a first-quarter loss of $25 million, or 26 cents per share, which surpassed Wall Street expectations. The genome editing company's revenue of $2.8 million, however, did not meet forecasts. Analysts had predicted a loss of 30 cents per share and revenue of $8.6 million.
Editas: Q1 Earnings Snapshot
Editas Medicine Inc. (EDIT) reported a first-quarter loss of $25 million, or 26 cents per share, which exceeded Wall Street expectations for loss per share. However, the company's revenue of $2.8 million fell short of analysts' forecasts. This data was generated by Automated Insights using Zacks Investment Research.
Editas Medicine (EDIT) to Release Quarterly Earnings on Monday
Editas Medicine (EDIT) is scheduled to release its Q1 2026 earnings before market open on Monday, May 11th, with analysts expecting an EPS of ($0.30) and revenue of $5.88 million. Despite beating estimates in the prior quarter, the company remains unprofitable, with institutional investors holding approximately 71.9% of the stock. Analyst consensus is a "Moderate Buy" with a target price of $5.30, while the stock currently trades around $2.99.
Editas Medicine (NASDAQ:EDIT) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Editas Medicine (NASDAQ:EDIT) from a "sell" to a "hold" rating, contributing to a consensus "Moderate Buy" rating among analysts with a $5.30 price target. The company recently beat Q1 earnings estimates with notable revenue, though it remains unprofitable. Editas Medicine is working on gene-editing therapies for conditions like LCA10 and sickle cell disease, with significant institutional ownership in the stock.
Editas Medicine (NASDAQ: EDIT) details 2026 virtual meeting, pay vote and in vivo strategy
Editas Medicine has released its definitive proxy statement for its 2026 virtual annual meeting, scheduled for June 17, 2026. Stockholders will vote on the election of two Class I directors, an advisory measure on executive compensation, and the ratification of PricewaterhouseCoopers as auditor. The company highlighted its strategic pivot to an in vivo gene editing model, featuring lead candidate EDIT-401 for LDL-cholesterol with over 90% preclinical reduction, and announced an extended cash runway into Q3 2027.
EDITAS Medicine (NASDAQ: EDIT) advances EDIT-401; IND target mid-2026
Editas Medicine (NASDAQ: EDIT) is advancing its lead gene editing candidate, EDIT-401, targeting hyperlipidemia with an IND submission planned for mid-2026, aiming for early human proof-of-concept by the end of 2026, and topline dose-finding results in 2027. The company's recent SEC filing details a focus on in vivo CRISPR gene editing after discontinuing its reni-cel program, as well as financial figures and intellectual property updates. EDIT-401 has shown significant LDL-C reduction in preclinical studies, and Editas continues to leverage collaborations and licensing to fund its pipeline.
Editas Medicine to present preclinical data on EDIT-401 therapy
Editas Medicine, Inc. announced upcoming presentations at scientific conferences in May, including preclinical data for EDIT-401, an in vivo CRISPR gene editing therapy aimed at lowering LDL-C in hyperlipidemia patients. Despite recent stock volatility, the company has seen significant year-to-date gains and has received "Buy" or "Outperform" ratings from multiple analysts, who highlight the progress of EDIT-401 towards clinical trials and the company's solid cash position. Editas Medicine also recently changed its accounting firm and saw a favorable ruling for the Broad Institute in a CRISPR patent dispute.
Upcoming Editas Medicine presentations focus on gene editing research advances
Editas Medicine announced it will present new preclinical data at upcoming scientific conferences, including ASGCT2026, TIDES USA, and EAS Congress 2026. The research will focus on recent developments in gene editing technologies and their potential applications, particularly in cardiovascular health. This initiative highlights the company's ongoing efforts to advance therapeutic solutions within the gene editing sector.
Editas Medicine to Present New Preclinical Data
Editas Medicine announced that it will present new preclinical data for EDIT-401, its lead in vivo development candidate for hyperlipidemia, at several upcoming scientific conferences. These presentations will include an oral presentation and two poster presentations at the ASGCT 2026 Annual Meeting, an oral presentation at TIDES USA 2026, and an oral presentation at the 94th European Atherosclerosis Society Congress. The data aims to demonstrate EDIT-401's potential as a transformative therapy for hyperlipidemia by upregulating LDLR protein to lower LDL-C.
Gene-editing cholesterol treatment heads to 3 scientific meetings
Editas Medicine announced that its gene-editing cholesterol treatment, EDIT-401, will be featured in five abstracts at three major scientific conferences in May 2026. The preclinical data presented will highlight the treatment's potential to upregulate LDLR and lower LDL-C levels in animal models, offering a new therapeutic approach for hyperlipidemia. While showing positive preclinical results, human clinical trial data for EDIT-401 has not yet been disclosed.
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
This article analyzes Editas Medicine's financial performance for Q1, highlighting a narrower loss per share than anticipated by analysts, alongside a year-over-year increase in revenues. This indicates a potentially positive financial trend for the company.
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates
Editas Medicine (EDIT) saw its shares increase after reporting fourth-quarter earnings and revenue that surpassed analyst estimates. The company posted an adjusted loss per share of $0.05 and revenue of $6.27 million, outperforming expectations. This positive financial performance led to a slight rise in its stock price.
Attachment
Editas Medicine has appointed Chi Li, Ph.D., MBA, RAC, as its new Senior Vice President and Chief Regulatory Officer. This announcement was made by the company today.
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from Analysts
Editas Medicine, Inc. (NASDAQ:EDIT) has an average "Moderate Buy" rating from analysts, with an average 1-year price target of $5.30. Institutional investors, including Renaissance Technologies and UBS, have significantly increased their positions, indicating strong investor confidence. Despite recent quarterly earnings beating expectations, the company remains unprofitable, with a negative net margin and projected negative EPS for the current year.
Editas Medicine (NASDAQ:EDIT) Downgraded by Wall Street Zen to Sell
Wall Street Zen has downgraded Editas Medicine (NASDAQ:EDIT) from a "hold" to a "sell" rating. Despite better-than-expected Q4 earnings with an EPS of $(0.06) and revenue of $24.74 million, the company remains unprofitable with a negative return on equity and net margin. Analysts for the current fiscal year forecast an EPS of -2.71, though the overall consensus rating for the stock is a "Moderate Buy" with an average price target of $5.30.
Editas Medicine, Inc. Files Form 8-K Announcing Changes in Certifying Accountant – April 2026
Editas Medicine, Inc. (NASDAQ: EDIT) has announced a change in its independent auditor, dismissing Ernst & Young LLP and appointing PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2026. This decision followed a formal review process by the Audit Committee, with no disagreements or "reportable events" cited between Editas and Ernst & Young. The company emphasized that this transition is a part of normal corporate oversight rather than a response to financial reporting concerns.
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Editas Medicine (EDIT) shares have risen 3.8% since its last earnings report, outperforming the S&P 500. The company reported a narrower-than-expected Q4 2025 loss and increased full-year revenues, primarily due to reduced operating expenses after discontinuing the reni-cel program. While estimates have shown an upward trend, indicating promise, the stock currently holds a Zacks Rank #3 (Hold) with an aggregate VGM Score of F.
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young By Investing.com
Editas Medicine announced the dismissal of Ernst & Young LLP as its independent registered public accounting firm, effective April 1, 2026, and has appointed PricewaterhouseCoopers LLP (PwC) as the new auditor for the fiscal year ending December 31, 2026. The decision followed a formal review, with Editas Medicine confirming no disagreements or reportable events with Ernst & Young. This change comes shortly after Editas Medicine reported strong fourth-quarter financial results and significant pipeline advancements.
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young
Editas Medicine (NASDAQ: EDIT) has appointed PricewaterhouseCoopers LLP (PwC) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026, dismissing Ernst & Young LLP. This decision followed a formal review process, with no disagreements or reportable events noted between Editas Medicine and Ernst & Young. The company also reported strong fourth-quarter financial results, exceeding analyst expectations.
Audit shakeup at Editas Medicine (NASDAQ: EDIT) as PwC replaces Ernst & Young
Editas Medicine (NASDAQ: EDIT) has formally replaced its auditor, dismissing Ernst & Young LLP and appointing PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026. This decision followed a thorough review process by the Audit Committee. The company explicitly stated there were no disagreements or reportable events with Ernst & Young during the prior audit periods, and their previous audit reports contained no adverse opinions, suggesting a smooth transition focused on governance rather than financial issues.
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates
The article reports that Editas Medicine (EDIT) shares saw a modest increase after the company announced its Q4 earnings and revenue exceeded analyst expectations.
EDIT Should I Buy
Editas Medicine Inc (EDIT) is not recommended as a strong buy for beginner or long-term investors due to weak financial performance, despite positive catalysts like a patent dispute win and increasing hedge fund interest. Revenue, net income, and EPS have seen significant year-over-year declines, and technical indicators suggest a neutral trend. Analysts hold mixed views, with one upgrade to 'Buy' and another downgrade while maintaining a 'Buy' rating.
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc
Editas Medicine Inc, a pioneer in CRISPR-based genome editing, continues to advance its drug pipeline despite sector challenges, with key programs targeting ocular, blood, and other disorders. The company, through its proprietary CRISPR/Cas9 platform, aims to develop one-time, curative treatments for inherited disorders, driven by a robust intellectual property portfolio and strategic partnerships. While facing intense competition and high risks typical of biotech, Editas's progress in clinical trials and potential partnerships represent critical inflection points for investors, particularly given its current market capitalization of $244 million and analyst forecasts suggesting upside potential.
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc
Editas Medicine Inc, a leader in CRISPR-based genome editing, is advancing its pipeline to address genetic diseases with its precise CRISPR/Cas9 platform. The company faces significant milestones with upcoming clinical data readouts and operates in a competitive biotech landscape against peers like CRISPR Therapeutics and Intellia Therapeutics. North American investors are keen on potential catalysts and strategic partnerships, despite the inherent risks and high volatility associated with development-stage biotech firms.
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program
Editas Medicine Inc. (EDIT) has confirmed EDT-401 as its lead in vivo program. This announcement highlights the company's focus on advancing this specific therapeutic candidate in its pipeline.
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology L
Editas Medicine Inc, a leader in CRISPR-based gene editing, is navigating clinical development challenges and competitive market hurdles. The company's lead program, EDIT-301, targets beta-thalassemia and sickle cell disease, showing promising preclinical data. Editas faces stiff competition from peers but differentiates itself through its broad patent estate and focus on both ex vivo and in vivo applications, continually striving to overcome technical and market obstacles in the promising field of gene therapy.
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology Landscape
Editas Medicine Inc, a leader in CRISPR-based gene editing, is navigating clinical development challenges and market hurdles despite its innovative technology. The company's lead program, EDIT-301, targets sickle cell disease and beta-thalassemia, with additional programs in ophthalmology and immuno-oncology. Analysts maintain a "hold" rating, reflecting the inherent risks and long-term potential in biotechnology investing, with success heavily dependent on clinical trial outcomes and competitive positioning.
CRISPR patent win bolsters Editas Medicine (NASDAQ: EDIT) IP estate
Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s decision favoring the Broad Institute in a key CRISPR/Cas9 patent interference, strengthening Editas's intellectual property estate. This ruling, the third such decision, confirms Broad as the first to invent CRISPR/Cas9 use in eukaryotic cells, with Editas holding exclusive licenses for these patents in medicine. The company highlighted that this reinforces confidence as they advance in vivo gene editing programs, including EDIT-401, which has shown significant LDL cholesterol reduction in non-human primates.
